ICCC logo

ImmuCell Corporation Stock Price

NasdaqCM:ICCC Community·US$54.9m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

ICCC Share Price Performance

US$6.07
1.13 (22.87%)
US$6.07
1.13 (22.87%)
Price US$6.07

ICCC Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Excellent balance sheet and slightly overvalued.

2 Risks
0 Rewards

ImmuCell Corporation Key Details

US$27.6m

Revenue

US$16.2m

Cost of Revenue

US$11.4m

Gross Profit

US$12.5m

Other Expenses

-US$1.0m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.11
41.40%
-3.76%
45.7%
View Full Analysis

About ICCC

Founded
1982
Employees
81
CEO
P. F. Te Boekhorst
WebsiteView website
immucell.com

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Recent ICCC News & Updates

Recent updates

No updates